Nevrargenics' CEO, Prof ANdy Whiting and Chief Medical Officer, Dr Tony Lockett, giving an interview at the Podcast of The Mark Sommerville Foundation for Motor Neuron Disease.
The Neuro Rehab Times ("NR Times"), published an article on Nebvargenics' lead drug candidate with the title "A pioneering study has revealed promising results for a new treatment targeting motor neurone disease (MND)".
Durham University publishes new findings on Ellorarxine™, Nevrargenics' breakthrough drug for Motor Neurone Disease, highlighting its potential for neuroprotection, neuroplasticity, and neurorepair in combating MND.
A new Pharmaceutical Manufacturer article highlights the neuroprotective effects of Ellorarxine™ in disease models, supporting its development for ALS and securing MHRA approval for upcoming human trials.
Reflections on Recent Developments in Alzheimer's Treatments
As a company dedicated to the fight against neurodegeneration, we at Nevrargenics commend all efforts that push the boundaries of treatment for these devastating diseases.
Bionow Neuroscience Conference, Sheffield, 17th July 2024. Our CEO, Prof Andy Whiting, presented the potential role that Nevrargenics might play in developing truly disease modifying drugs.
Nevrargenics proudly participated at a prestigious event in London, right across from the Big Ben and next to St Thomas's Hospital. The event brought together a dynamic group of investors.
The Scientific Advice meeting with the UK Medicines and Healthcare Products Regulatory Agency (MHRA) was held to discuss Nevrargenics’ Motor Neurone Disease drug candidate, NVG0645.
Research Features published an article on us entitled "Nevrargenics: Neuroprotection, neuroplasticity, and neurorepair" about the background to, and summary of, our drug development programme.
Nevrargenics participates in Bio Europe
We were delighted to take part in Bio Europe Spring 2023 in Basel, Switzerland and have over 30 one-to-one meetings with pharmaceutical companies for potential deals.